Mit Ihrer Erlaubnis verwenden wir datenschutzfreundliche Analysen, um zu verstehen, welche Recherchewege funktionieren. Wir verwenden weder Werbe-Tracker noch Sitzungsaufzeichnungen. Sie können diese Auswahl in den Einstellungen ändern. Lesen Sie die Datenschutzerklärung.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
GEHC — frequently asked questions
Is GE HealthCare Technologies Inc. overvalued?
In our latest published analysis dated 2026-10-05, GEHC looks modestly undervalued. The price recorded at analysis is 64,3 USD versus our fair value of 68,3 USD; the high endpoint is presented separately as potential value of 81,1 USD. That implies roughly 6.2% upside to fair value at that date.
Our latest published report, analyzed 2026-10-05, gives GEHC a fair value of 68,3 USD and a potential value of 81,1 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for GE HealthCare Technologies Inc.'s archetype; it is a dated research output, not a live price.
Should I buy GEHC now?
Our latest published rating for GEHC, analyzed 2026-10-05, is Hold. GE HealthCare Technologies Inc. looks modestly undervalued at the analysis-date price of 64,3 USD versus fair value of 68,3 USD; potential value is 81,1 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for GEHC?
The dedicated bear-case section in our report analyzed 2026-10-05 documents GE HealthCare Technologies Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is GEHC's rating?
Our latest published rating for GEHC, analyzed 2026-10-05, is Hold, with a published moat assessment of 7.5/10 (Narrow). It reflects our fair value of 68,3 USD, the potential value of 81,1 USD, and the price recorded at analysis (64,3 USD).
Englische Quelle wird angezeigt, während wir übersetzen
Dieser Bericht wurde noch nicht übersetzt. Aktualisieren Sie in ein paar Minuten, sobald die Übersetzungswarteschlange aufgeholt hat.
§1 ZusammenfassungEN
30-Sekunden-AntwortHold
Preis im Verhältnis zum Wert
Kurs
$64.29
Fairer Wert
$68.29
Potenzialwert
$81.12
Stand
2026-10-02
Warum es funktionieren kann
Accelerating replacement cycles across the global installed base through artificial intelligence-enabled imaging platforms, combined with post-spin margin expansion toward medtech industry averages of 15.50%, represents the biggest opportunity to drive equity value toward Potential value of USD 81.12 per share.
Was unsere Einschätzung ändern würde
Imaging segment annual revenue growth falling below 0.0% year-over-year in FY2026 or FY2027.
We assign GE HealthCare Technologies Inc. a Hold rating with a Fair value of USD 68.29 per share, as recurring diagnostic imaging service revenues are balanced by hospital equipment budget constraints and modest valuation upside,.
A Hold rating indicates that GE HealthCare offers balanced risk and reward at current valuation levels, meaning investors should maintain existing portfolio allocations rather than committing fresh capital or exiting positions. Core revenue stability provides a dependable foundation, but near-term upside remains limited without a wider margin of safety.
The report was prepared at a price of USD 64.29 on October 2, 2026. That report-date price sits 5.86% below our house Fair value of USD 68.29 per share, representing an implied return of 6.22%. reaches USD 81.12 per share if fleet replacement cycles and operational efficiency accelerate.
The primary downside risk centers on hospital capital expenditure deferrals. Diagnostic imaging generated USD 9,245,000,000, or 44.82% of consolidated sales in FY2025,. If health systems tighten capital budgets and postpone major diagnostic equipment upgrades, Imaging segment revenue growth would turn negative, reducing high-margin post-warranty service agreements and compressing operating profit margins.5,6
The primary investment catalyst is the steady conversion of the company's entrenched global installed base. By upgrading existing hospital scanner networks with artificial intelligence and proprietary diagnostic software, GE HealthCare expands high-margin service contracts, which generated USD 1,988,000,000 in operating cash flow in FY2025. Expanding service attach rates and standalone supply chain efficiencies lift earnings per share toward Potential value of USD 81.12 per share.4,6
Entrenched Diagnostic Installed Base and Recurring Service Revenue
Imaging generated USD 9,245,000,000 in FY2025 (44.82% of consolidated revenue), anchoring high clinical switching costs and multi-year maintenance service agreements across hospitals worldwide,.5,6
Attractive Valuation Headroom Relative to Medical Technology Peers
Trading at a forward price-to-earnings ratio of 12.12x, GE HealthCare provides valuation discount protection against medtech peers trading above 16x to 27x forward earnings,.3,4
Hausempfehlung
We assign a Hold rating because GE HealthCare's stable diagnostic imaging installed base and recurring service cash flows are balanced by hospital capital spending constraints and limited near-term valuation upside,.6
Unternehmensüberblick
GE HealthCare Technologies Inc. is a global medical technology provider that develops, manufactures, and services diagnostic imaging systems, patient monitoring solutions, and digital healthcare technologies. The company's products operate across clinical health systems and reside within customer on-premise and cloud information technology infrastructures, incorporating specialized cybersecurity architectures to protect confidential patient data.
Operations are organized into four reportable segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The core Imaging segment includes Molecular Imaging, Computed Tomography, Magnetic Resonance, Women's Health, and X-ray product lines, supported by enterprise software and multi-year field service agreements.
GE HealthCare serves hospitals, clinical health systems, and specialty healthcare providers across international markets. Its offerings support clinicians across a broad spectrum of medical specialties, including oncology, cardiology, neurology, nuclear medicine, orthopedics, women's health, pediatrics, and surgical care.
§2 BärenszenarioEN
In a severe compounding downturn, multiple structural headwinds strike simultaneously. Hospital operating margins remain compressed, prompting health systems to defer major diagnostic scanner upgrades, pushing Imaging segment revenue growth to -5.0% and dragging consolidated sales growth below baseline expectations. Concurrently, aggressive expansion of centralized volume-based procurement and domestic preference policies in China ($2,031,000,000 FY2025 revenue) force double-digit price cuts, driving group operating margin down toward 10.40% (a 300 bps contraction from FY2025's 13.40%). In the capital markets, an environment of persistent inflation pushes the cost of capital above 8.75% as the company refinances portions of its $10,540,999,680 total debt burden. Investors de-rate the equity to a cyclical equipment multiple of 9.7x. Under this joint stress scenario, enterprise cash flow generation diminishes significantly, pulling intrinsic value toward the lower bound of $52.82.
Severe Hospital Capital Equipment Freeze and Imaging Deferral
Imaging represents 44.82% of consolidated sales ($9,245,000,000 in FY2025). Persistent macroeconomic pressures, elevated borrowing rates, and hospital operating budget strains could force healthcare networks to freeze capital expenditures and postpone diagnostic scanner replacements. A drop in Imaging growth below -5.0% would depress 5-year consolidated revenue expansion and reduce high-margin service contract renewals.6
FV impact
-5.2%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 12 months
Frühwarnsignale zur Überwachung
Die fünf Entwicklungen, die unsere Anlagethese schwächen würden.
Negative growth in Imaging indicates that hospital capex budget freezes are halting equipment upgrade cycles, impairing the foundation of total company revenue and future high-margin service agreements.
Aktuell:5.32% projected FY2026 revenue growth on $9,245,000,000 FY2025 baseline
§3 WettbewerbsgrabenEN
Narrow
GE HealthCare maintains a Narrow economic moat grounded in substantial customer switching costs, proprietary diagnostic technology, and unmatched global service distribution density. The core moat engine resides in its Imaging segment, which generated $9,245,000,000 in FY2025, or 44.82% of consolidated sales ($20,625,000,000),. Large-scale diagnostic imaging installations—including computed tomography (CT), magnetic resonance (MR), and molecular imaging systems—are capital-intensive, mission-critical assets deeply embedded in hospital clinical routines and enterprise electronic health record (EHR) infrastructures. Transitioning to a competing platform imposes severe retraining demands on clinical radiology staff, architectural modifications, and substantial operational disruption, which naturally creates high customer inertia and high multi-year contract renewal rates.
Complementing switching costs, the company leverages significant intangible assets across proprietary scan reconstruction algorithms, digital clinical tools, and patented molecular radiopharmaceutical tracers in its Pharmaceutical Diagnostics segment ($2,900,000,000 FY2025 sales). Furthermore, with an active global installed base exceeding four million systems, GE HealthCare deploys an extensive field service engineer network that provides guaranteed rapid-response maintenance, creating a service density advantage that emerging competitors cannot replicate economically. This competitive advantage translates into economic profit: return on invested capital stands at 11.38%, consistently generating an excess economic spread above its computed weighted average cost of capital of 7.75% and moderate cost of equity of 8.94%, supported by durable annual operating cash flow of $1,988,000,000.
Despite these strengths, the moat is classified as Narrow rather than Wide due to structural industry characteristics. Capital equipment purchasing is intrinsically tied to hospital capital budget cycles, which periodically exposes hardware sales to deferred replacement schedules during economic slowdowns. Additionally, intense competition from well-capitalized global peers such as Siemens Healthineers and Philips in diagnostic imaging hardware necessitates ongoing research and development spending, while rapid-cycle advancements in third-party diagnostic software and centralized procurement policies in markets like China ($2,031,000,000 FY2025 revenue) constrain competitive advantage visibility beyond a ten-year projection horizon.
Ökonomischer Gewinn
Economic profit generation is demonstrated by a return on invested capital of 11.38%, consistently surpassing both the computed weighted average cost of capital of 7.75% and the moderate cost of equity of 8.94%. Generating $1,988,000,000 in operating cash flow on $20,625,000,000 in FY2025 revenue reinforces that the company earns sustainable returns in excess of its capital costs.2,4,5
7.5/ 10
Narrow
Sources of advantage
01High Customer Switching Costs — Diagnostic imaging suites represent multi-million dollar investments integrated into hospital IT and clinical architectures. High retraining costs for radiology staff and operational disruption from replacing hardware drive customer lock-in and multi-year service contract attach rates.Wide
02Intangible Assets (Proprietary Diagnostic Technology & Patents) — Extensive patent portfolios covering advanced imaging reconstruction, digital clinical applications, and specialized proprietary contrast agents and radiopharmaceuticals in Pharmaceutical Diagnostics ($2,900,000,000 sales in FY2025) create durable barriers to entry.Moderate
03
Bekannte Bedrohungen für den Wettbewerbsvorteil
Bedrohung
Schweregrad
Zeitrahmen
Minderung
Rapid Advancements in Artificial Intelligence and Vendor-Neutral Diagnostic Software
medium
3-5 years
Integrating proprietary artificial intelligence algorithms natively into scanner edge processing hardware and expanding open digital health platforms.
Expansion of Centralized Volume-Based Procurement and Domestic Preference Mandates in China
The highlighted cell is Fair value when every assumption sits at its base level ($68.29). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $2.0B after modeled reinvestment of $221.4M, with terminal value at 78.1% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
The Base scenario projects a target of $68.29 with an assigned probability of 60.0%, representing an expected return of 6.2% relative to $64.29 (as of 2026-10-02). This path requires steady execution across core diagnostic imaging replacement cycles, durable recurring service revenues, and gradual operating margin expansion from standalone supply chain efficiencies. The scenario would be disconfirmed if hospital equipment procurement decelerates into contraction or if pricing concessions in international markets impair gross margin stability. Investors will be able to verify this trajectory through book-to-bill ratios and quarterly imaging segment growth across upcoming reporting periods.
Upgrade the rating; Re-examine capital equipment upgrade velocity and consider expanding portfolio allocation if service contract expansion proves durable.
A sustained acceleration in diagnostic equipment delivery coupled with higher margin service contract attach rates demonstrates that hospital procurement cycles are expanding faster than modeled.
Im Plan
Maintain Hold; Maintain position allocation and monitor upcoming quarterly order intake and book-to-bill ratios across core imaging modalities.
Auslöser: Consolidated revenue and diluted earnings matching consensus projections with stable hospital replacement demand
Operating results track the modeled replacement cycle baseline, showing that steady domestic execution balances ongoing tender scrutiny and localized pricing pressure.
Verfehlt
Downgrade the rating; Trim portfolio allocation, re-underwrite medium-term earnings trajectory, and evaluate whether equipment deferrals reflect temporary delays or structural share loss.
Widespread hospital capital expenditure deferrals or intensified centralized procurement price concessions would compress operating profitability and impair cash flow generation.
Ergebnisqualität
Earnings quality is supported by healthy cash conversion from net income to operating cash flow, reflecting disciplined working capital management across receivables and inventory post-spin-off. The recurring nature of high-margin service contracts and consumables provides stable earnings visibility. Sustained free cash flow generation comfortably covers annual capital reinvestment and debt service requirements, while stock-based compensation remains modest relative to operating profits. However, persistent capitalization of software development or unexpected working capital build-ups in equipment inventory would signal slowing backlog conversion and require immediate review.
Dynamik der Schätzungen
Consensus revenue and earnings expectations have remained largely flat following the recent quarterly earnings release, reflecting steady execution across core imaging modalities and stable hospital service backlogs. Analyst revisions indicate a balanced outlook where solid North American equipment demand is counterbalanced by measured purchasing timelines in China and broader hospital capital budget discipline.
Wichtige Kennzahlen vor dem Bericht
01
Kennzahl:
Imaging Segment Revenue and Replacement Cycle Momentum
AktuellGenerating the largest segment contribution to consolidated revenue with steady demand across computed tomography and magnetic resonance systems in North America.
Warum es wichtig ist
Imaging represents the foundational core of total revenue and drives recurring service contracts; slowing replacement cycles would compress consolidated organic growth and reduce operating leverage.
§8 Finanzielle Historie
Gewinn- und Verlustrechnung — letzte sechs Perioden
GE HealthCare demonstrated solid cash conversion in FY2025, generating $1,988,000,000 in operating cash flow and $1,505,000,000 in free cash flow after capital expenditures of $482,000,000,. Operating cash flow conversion relative to net income of $2,084,000,000 was 95.39%, underscoring solid earnings quality and absence of aggressive accruals. Depreciation and amortization of $578,000,000 exceeded capex ($482,000,000), highlighting that capital intensity remains modest at 2.34% of revenue, leaving substantial free cash flow for debt service and strategic investments.4
Stable ROIC trajectory reflects durable returns from the mission-critical installed imaging base and steady high-margin service contracts. Post-spin operating margin normalization from 13.40% in FY2025 toward 14.20% by FY2030 provides modest return expansion while disciplined capital expenditure keeps invested capital lean.
Consistently positive economic spread: ROIC of 11.38% vs computed WACC of 7.75% (7.7493%) and moderate cost of equity of 8.94%.
High Cash Flow Conversion Anchored by Non-Deferrable Service Contracts
Operating cash flow reached $1,988,000,000 in FY2025 against of $2,084,000,000, delivering 95.39% conversion.
Jüngster Umsatz20,6 Mrd. $Umsatz-CAGR +3,7 %
Betriebsmarge13,4 %7 Geschäftsjahresperioden
Jüngster freier Cashflow1,5 Mrd. $FY2025
Nettoverschuldung5,5 Mrd. $FY2025
Aufschlüsselung der Gewinn- und VerlustrechnungWie sich die Unternehmensgröße in ausgewiesenen Gewinn übersetzt.30. Juni 2026
GE HealthCare Technologies Inc. (GEHC) trades at 12.1x forward earnings against a peer median of 20.8x. Its EV/EBITDA of 10.5x compares with a peer median of 19.3x. The comparison uses 4 peers: DexCom Inc., Boston Scientific Corporation, Edwards Lifesciences Corporation and Stryker Corporation, as of 2026-10-04 to 2026-10-05.
§10 Branche & ZyklusEN
Zyklusphase
Expansion
Industry capital expenditures relative to revenue stand at 4.50% (0.045) and capex-to-depreciation is 0.80x. For GE HealthCare, FY2025 capital expenditures were $482,000,000 on revenue of $20,625,000,000 (capex/revenue 2.34%), and depreciation was $578,000,000 (capex/depreciation 0.8339). Because capacity, supply lead times, and customer concentration data are limited, the cycle view is demand-led and evidence-limited.5
Bullenzyklus
During an industry upcycle, healthcare providers experience expanding operating margins, robust elective and diagnostic procedure volumes, and lower financing costs. This environment accelerates multi-year capital replacement programs for high-end CT, MR, and molecular imaging suites, while driving rapid hospital adoption of AI-enabled diagnostic clinical software and premium contrast media.
Bärenzyklus
In an industry downcycle, hospital operating margins tighten due to elevated labor expenses and public funding constraints, while high borrowing rates elevate the cost of capital. Healthcare CFOs respond by extending equipment operational lifespans beyond customary 7-to-10-year replacement cycles, deferring large-scale capital purchases, and relying on essential service agreements rather than purchasing new hardware.
Säkulare Trends
Trend
Auswirkung
Hinweis
Global Demographic Aging and Expanding Chronic Disease Prevalence
positive
Aging populations across North America, Europe, and Asia generate steadily increasing procedural volumes in oncology, cardiology, and neurology, driving structural demand for diagnostic imaging and radiopharmaceuticals.
Clinical Artificial Intelligence Integration and Precision Medicine
positive
Hospital staffing shortages drive demand for automated scan positioning, accelerated MRI acquisition sequences, and AI-assisted lesion detection to boost clinician productivity.
Positionierung
GE HealthCare occupies an entrenched mid-to-high competitive positioning across diagnostic imaging ($9,245,000,000 FY2025 revenue) and patient monitoring ($3,086,000,000 PCS revenue). Its broad geographic diversification, anchored by the stable US healthcare market ($9,168,000,000 revenue), insulates group cash flows against regional tender delays, although its capital equipment tilt exposes it to greater cyclicality than pure-play medical consumable peers.6
§11 PositionsmanagementEN
Positionsgröße
2.0-3.0%
A neutral allocation of 2.0-3.0% reflects a Hold rating on a mature compounder trading at $64.29 with an implied upside of 6.22% to Fair value of $68.29. While the entrenched imaging installed base and 12.12x forward P/E offer downside support, limited immediate valuation discount and hospital budget cross-currents warrant maintaining an existing position rather than aggressively expanding.4
Risiko
Risk management focuses on sizing exposure in accordance with the 6.22% implied return to Fair value of $68.29. Given that 44.82% of revenue resides in the capital-intensive Imaging segment and $10,540,999,680 of total debt must be serviced, investors should maintain disciplined portfolio allocation without chasing rallies above Fair value. Macro interest rate spikes and China tender headwinds represent key exogenous risks requiring vigilant monitoring of quarterly order backlogs and debt covenant coverage.
Einstiegstranchen
Niveau
Aktion
Warum
$58.00 - $60.00
Initial Accumulation / Tranche 1
At $58.75 (52-week low) to $60.00, the stock trades at an ~12-15% discount to Fair value ($68.29) and ~11.0x forward earnings, offering attractive risk-adjusted margin of safety.
Demote multi-year revenue growth path from 4.4% to below 2.5% and downgrade rating toward Reduce.6
§12 Investoren-PerspektivenEN
Value Investor
Hold
Trading at a forward price-to-earnings ratio of 12.12x, the stock trades at an attractive discount to medical technology peers,. However, an implied return of 6.22% to Fair value does not yet provide an adequate margin of safety to justify new capital allocation.3,4
Growth Investor
Avoid
Revenue growth is projected at 5.32% in FY2026 and 4.60% in FY2027, which represents mature single-digit compounding rather than the rapid double-digit expansion sought by high-growth healthcare investors,.1
Defensive Investor
Hold
Substantial recurring revenue from multi-year service contracts and robust operating cash flow of USD 1,988,000,000 provide strong downside resilience against broader economic volatility.4
§14 Endgültige EmpfehlungEN
Aktion
Halten
Maintain existing portfolio exposure to GE HealthCare while awaiting clearer signs of hospital equipment capital budget expansion or a wider margin of safety below our Fair value midpoint of USD 68.29 per share,.
While the core installed base and high-margin service contracts provide dependable cash flow generation, an implied upside of 6.22% at the report-date price of USD 64.29 on October 2, 2026 does not meet the hurdle rate for initiating new capital commitments,.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-10-05 · Published 2026-10-05 · Provider-adjusted · cited for 1 figureCited in Investoren-Perspektiven
Market and peer researchData as of 2026-10-05 · Published 2026-10-05 · Provider-adjusted · cited for 1 figureCited in Zusammenfassung, Investoren-Perspektiven
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
The Bear scenario models a severe downturn where prolonged hospital capital expenditure freezes force healthcare systems to defer diagnostic equipment replacements, dragging consolidated top-line growth into negative territory. Concurrently, intensifying centralized procurement scrutiny and local substitution mandates in China lead to aggressive pricing concessions, compressing operating profitability. Downside risks are further compounded if refinancing costs on corporate debt escalate in a restrictive interest rate environment. This stress case would be confirmed if imaging equipment order intake contracts or if gross margins experience sharp deterioration across consecutive quarterly filings.
China Healthcare Anti-Corruption Escalation and Volume-Based Procurement Price Collapse
Revenue from China reached $2,031,000,000 in FY2025 (9.85% of total sales). An intensification of healthcare sector anti-corruption scrutiny alongside expanded volume-based procurement tenders and domestic champion preferences could force 20% to 30% price concessions. The resulting operating deleverage would contract consolidated operating margins below 10.40% (over 300 bps below FY2025's 13.40%), severely compressing earnings.6
GE HealthCare trades at a forward P/E of 12.12x against an assumed terminal P/E of 14.0x. Persistent gross margin pressure (historical gross margin falling from 41.71% to 39.99%) and balance-sheet liquidity metrics in the caution zone could induce the market to reclassify the business as a cyclical equipment manufacturer rather than a premium medtech compounder, re-rating the multiple by 20% down to 9.7x terminal P/E.4
FV impact
-4.8%
Terminal multiple 20% lower
Trigger
Within 12 months
Macro Interest Rate Spike and Debt Refinancing Squeeze
The company carries $10,540,999,680 in total debt with a computed WACC of 7.75% (7.7493%). Higher benchmark interest rates and credit spread widening upon refinancing spin-off debt maturities could elevate WACC by over 100 bps to exceed 8.75%, materially discounting enterprise DCF values.2
A drop exceeding 20% indicates that volume-based procurement price cuts and domestic manufacturing substitution are systematically eroding Chinese market share.
Aktuell:$2,031,000,000 in FY2025 (9.85% of total sales)
WACC climbing past 8.75% due to higher sovereign yields or wider credit spreads on $10,540,999,680 of total debt increases annual debt service costs and heavily discounts enterprise cash flows.
A decline in cash conversion below 70% would indicate aggressive revenue recognition, extended receivables collection cycles in emerging markets, or unexpected working capital lock-up in unsold equipment inventories.
Aktuell:95.39% in FY2025 ($1,988,000,000 OCF / $2,084,000,000 net income),
Alarm, wenn< 70.0% trailing twelve months
Scale Advantage and Global Service Distribution Density
— With consolidated sales of $20,625,000,000 and an installed base of over 4 million systems globally, the company's dedicated field engineer network provides rapid on-site maintenance that regional competitors cannot match economically.
Moderate
medium
1-3 years
Deepening local manufacturing, domestic supply chain sourcing, and developing specialized value-tier product lines within China.6
Consolidation of Healthcare Group Purchasing Organizations (GPOs) Squeezing Equipment Capital Budgets
low
2-4 years
Engaging health systems through long-term enterprise fleet management and efficiency partnerships that tie procurement to measurable clinical productivity.
Discounted forecast-period cash flows (19,12 $) plus discounted terminal value (68,03 $) minus signed per current share (12,11 $) equals the 75,03 $ lens value shown above. Negative net debt is , so subtracting it raises value.
Stabilization and policy recovery in China tender activity restores emerging market revenue growth
The Bull scenario projects a target of $81.12 with an assigned probability of 20.0%, offering an implied return of 26.2% compared to $64.29 (as of 2026-10-02). Realizing this potential value path requires accelerated hospital fleet modernization driven by artificial intelligence integration, robust post-spin supply chain rationalization, and a sharp rebound in public healthcare procurement across emerging markets. This thesis would be falsified if customer adoption of new digital features stalls or if hospital capital budget constraints cap equipment pricing. Investors will assess progress through sequential order momentum and margin leverage across upcoming fiscal quarters.
02
Kennzahl:
China Centralized Procurement and Healthcare Tender Activity
AktuellRegional sales represent a bounded minority of consolidated revenue while navigating ongoing public tender reviews and localized pricing policies.
Warum es wichtig ist
Protracted anti-corruption scrutiny and centralized volume-based procurement concessions in China threaten regional margins and create top-line drag unless domestic demand stabilizes.
AktuellOperating profitability remains resilient and tracks post-separation efficiency targets while absorbing higher component costs and competitive pricing.
Warum es wichtig ist
Post-spin standalone cost optimization and supply chain productivity must expand margins toward medical technology peer medians to support multi-year earnings compounding.
Robust operating cash generation is required to service post-separation debt obligations, reinvest in software and digital platforms, and maintain balance sheet flexibility.
05
Kennzahl:
North American Hospital Capital Equipment Budgets
AktuellUnited States sales serve as the primary revenue anchor, exhibiting steady procedural volume and resilient clinical equipment demand.
Warum es wichtig ist
Because the United States represents the company's primary profit engine, shifts in hospital operating margins or elevated borrowing costs directly govern large-scale diagnostic equipment purchasing.
Capital allocation post-spin reflects disciplined debt reduction, prudent reinvestment, and modest shareholder distributions. In FY2025, operating cash flow of $1,988,000,000 funded capital spending of $482,000,000, dividends of $64,000,000, and share repurchases of $200,000,000,. Net debt stood at $5,511,000,000 ($10,003,000,000 total debt offset by $4,492,000,000 cash), with total debt as of 2026-10-05 reported at $10,540,999,680. Management prioritizes maintaining investment-grade credit metrics over aggressive buybacks, ensuring refinancing flexibility.
Cash flow stability shields the enterprise from hospital hardware purchasing pauses and ensures dependable self-funding of software R&D.
Low Capital Intensity Drives Resilient Free Cash Generation
FY2025 capital expenditures were $482,000,000 (2.34% of sales) vs D&A of $578,000,000 (capex/D&A 0.8339),.
Unlike heavy industrial equipment manufacturing, medtech imaging requires modest maintenance capex (modeled at 85% of capex), freeing over $1.5B annually in free cash flow.
Centralized Public Procurement and Anti-Corruption Enforcement in Emerging Markets
negative
Policy shifts toward centralized volume-based procurement (VBP) and hospital expenditure audits in China and developing markets create periodic tender delays and unit pricing pressure.
China regional sales decline
> 20.0% YoY decline in any single fiscal period
Isolate China contribution and lower group operating margin normalization target by 50 bps.6
